Gatehouse Bio Extends Its Partnership with AstraZeneca to Develop RNA Therapeutics for Heart Failure
BOSTON–(BUSINESS WIRE)–Gatehouse Bio, a pioneer in small RNA therapeutics, and AstraZeneca, a global, science-led biopharmaceutical company, are advancing their partnership, to create RNA therapeutics for the treatment of heart failure with preserved ejection fraction (HFpEF).
Collaboration will use Gatehouse Bio’s AI-Powered Analytics Platform to identify potential drug targets in respiratory and cardiovascular diseases
Platform uncovers biomarkers that track progression of Huntington’s disease 20 years before symptomatic onset
… early-stage biotech startup based in Boston who has developed a software platform technology to identify small RNA biomarkers, announced today it will participate in the IndieBio Accelerator Program in San Francisco, CA.